Brief introduction

This poster evaluates whether plasma p-tau217 can predict tau PET positivity across multiple assay platforms and whether double-cutoff strategies can improve cost-effective triage for confirmatory tau PET. Across a tau-enriched K-ROAD cohort and a tau-scarce NA-ADNI cohort, plasma p-tau217 showed good discrimination for tau PET positivity. Double-cutoff approaches modestly improved classification and may help reduce misclassification-related costs by routing uncertain cases to confirmatory tau PET rather than replacing tau PET universally.

Keywords

Alzheimer’s disease; plasma p-tau217; tau PET; tau PET positivity; double cutoff; single cutoff; biomarker triage; confirmatory tau PET; cost-effectiveness; misclassification; assay platform; K-ROAD; ADNI; amyloid positivity; Alzheimer’s biomarkers